PTGX
Protagonist Therapeutics Inc
NASDAQ: PTGX · HEALTHCARE · BIOTECHNOLOGY
$98.97
+0.46% today
Updated 2026-04-30
Market cap
$6.34B
P/E ratio
—
P/S ratio
137.68x
EPS (TTM)
$-2.05
Dividend yield
—
52W range
$41 – $108
Volume
0.8M
Protagonist Therapeutics Inc (PTGX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-7.74M | $-14.38M | $-29.97M | $3.87M | $-49.95M | $-41.53M | $-72.48M | $-107.86M | $-108.14M | $-70.24M | $184.15M | $57.67M |
| Capital expenditures | $299000.00 | $399000.00 | $379000.00 | $666000.00 | $486000.00 | $967000.00 | $471000.00 | $1.10M | $795000.00 | $609000.00 | $1.35M | $1.59M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $42000.00 | $99000.00 | $2.13M | $4.24M | $6.92M | $8.35M | $7.90M | $16.39M | $24.20M | $29.29M | $37.55M | $45.97M |
| Free cash flow | $-8.04M | $-14.78M | $-30.35M | $3.21M | $-50.43M | $-42.49M | $-72.95M | $-108.97M | $-108.93M | $-70.84M | $182.80M | $56.08M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $17.03M | $85.25M | $-23.62M | $-49.20M | $84.18M | $6.20M | $2.17M | — | — | — |